ProPhase Labs, Inc. Additional Paid in Capital, Common Stock
ProPhase Labs, Inc. (PRPH) had Additional Paid in Capital, Common Stock of $54.70 million as of 2015-03-31, per its 10-Q filed 2015-05-13.
Discontinued › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2015-05-13
- 2015-03-31: Additional Paid in Capital, Common Stock $54.70M.
- 2014-12-31: Additional Paid in Capital, Common Stock $54.66M.
- 2014-09-30: Additional Paid in Capital, Common Stock $53.81M.
- 2014-06-30: Additional Paid in Capital, Common Stock $48.56M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2015-03-31 | $54.70M 10-Q · filed 2015-05-13 |
| 2014-12-31 | $54.66M 10-Q · filed 2015-05-13 |
| 2014-09-30 | $53.81M 10-Q · filed 2014-11-13 |
| 2014-06-30 | $48.56M 10-Q · filed 2014-08-12 |
| 2014-03-31 | $44.62M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $43.61M 10-K · filed 2015-03-27 |
| 2013-09-30 | $43.23M 10-Q · filed 2013-11-13 |
| 2013-06-30 | $43.14M 10-Q · filed 2013-08-13 |
| 2013-03-31 | $43.10M 10-Q · filed 2013-05-10 |
| 2012-12-31 | $42.87M 10-K · filed 2014-03-27 |
| 2012-09-30 | $41.76M 10-Q · filed 2012-11-14 |
| 2012-06-30 | $41.72M 10-Q · filed 2012-08-13 |
| 2012-03-31 | $41.64M 10-Q · filed 2012-05-11 |
| 2011-12-31 | $41.55M 10-K · filed 2013-03-28 |
| 2011-09-30 | $41.24M 10-Q · filed 2011-11-14 |
| 2011-06-30 | $41.11M 10-Q · filed 2011-08-12 |
| 2010-12-31 | $40.63M 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |